Source: Cyclo Therapeutics, Inc. 10/4/19
Cyclo Therapeutics, Inc. (OTCQB: CTDH) announced today that it has
completed its name change from CTD Holdings, Inc. following appropriate
regulatory filings with the State of Florida and FINRA. The new name
better reflects the company’s business as a biotechnology company that
develops cyclodextrin-based products for the treatment of disease with
unmet medical need, most notably Trappsol® Cyclo™, its
proprietary hydroxypropyl beta cyclodextrin drug, for the treatment of
Niemann-Pick Disease Type C and Alzheimer’s Disease. The company will
continue to trade on the OTCQB Exchange under the symbol CTDH. The new
name was overwhelmingly approved by shareholders at their meeting on
August 27th.
“As we continue to develop our clinical programs in disease areas that can be potentially treated with Trappsol®
Cyclo™, the Cyclo Therapeutics, Inc. name better reflects the Company’s
main business going forward. We look forward to continued progress and
higher recognition of our important biopharmaceutical products,” said
Company Chairman & CEO, N. Scott Fine.
About Cyclo Therapeutics:
Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company that
develops cyclodextrin-based products for the treatment of disease. The
company’s Trappsol® Cyclo™, an orphan drug designated product
in the United States and Europe, is in three ongoing formal clinical
trials for Niemann-Pick Disease Type C, a rare and fatal genetic
disease, (Clinical Trials.gov NCT02939547, NCT02912793 and NCT03893071)
and in an Expanded Access program for late-onset Alzheimer’s Disease
(NCT03624842). Additional indications for the active ingredient in
Trappsol® Cyclo™ are in development. For additional information, visit the company’s website: www.cyclotherapeutics.com
No comments:
Post a Comment